Breast Cancer Now media statements
We respond to research that suggests drugs that neutralise progesterone activity could be a potential risk-reducing treatment for women with altered BRCA genes
In response to research published in Genome Medicine, and part-funded by Breast Cancer Now, which suggests drugs that neutralise progesteron...
We respond to the Royal College of Radiologists’ clinical radiology and clinical oncology census reports for 2021
In response to today’s Royal College of Radiologists’ clinical radiology and clinical oncology censuses, Baroness Delyth Morgan, Chief Execu...
We respond to new findings from the Lumina trial which suggest some patients could avoid radiotherapy
Breast Cancer Now has commented on findings from the Lumina trial presented at the American Society of Clinical Oncology (ASCO).
We comment on new research which shows the drug trastuzumab deruxtecan may benefit even more breast cancer patients
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We welcome NICE approval of pembrolizumab (Keytruda) in combination with chemo (paclitaxel or nab-paclitaxel) for routine use on the NHS
Responding, Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We comment on saliva samples used to determine breast cancer risk in women of screening age
We have commented on new research published in Genetics in Medicine titled 'Breast cancer risk stratification in women of screening age: Inc...
We support latest Emmerdale storyline on Faith Dingle's Secondary Breast Cancer diagnosis
Catherine Priestley, Clinical Nurse Specialist at Breast Cancer Now, said:
We respond to new research into how salt in tumours could help diagnose and treat breast cancer
New research, funded by Breast Cancer Now and Cancer Research UK at the universities of York and Cambridge, has shown that analysing sodium ...
We respond to NICE provisional decision not to recommend alpelisib with fulvestrant for routine use on the NHS
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to research about artificial sweeteners and breast cancer risk
Commenting on research published in PLOS Medicine about artificial sweeteners and breast cancer risk, Dr Kotryna Temcinaite, Senior Research...
We respond to new data from major trial OlympiA shows adjuvant olaparib improved survival in patients
On 16 March new findings from the OlympiA phase III trial were presented at a virtual plenary session from the European Society for Medical ...
We respond to NHS England's proposed new standards
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said: